menu search

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...

June 3, 2023, 1:00 pm

Apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of cl

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free surv...

June 3, 2023, 12:00 pm

Apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of cl

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free surv...

June 3, 2023, 12:00 pm

Apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of cl

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free surv...

June 3, 2023, 12:00 pm

Apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of cl

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free surv...

June 3, 2023, 12:00 pm

Apexigen announces phase 2 data evaluating sotigalimab, its cd40 agonist antibody, in combination with doxorubicin in patients with advanced soft tissue sarcoma presented at the american society of cl

– Marked increases in overall survival observed across soft tissue sarcoma patients – – Demonstrated improvement of median progression free surv...

June 3, 2023, 12:00 pm

Zevra therapeutics presents design of phase 2 clinical trial investigating kp1077 for the treatment of idiopathic hypersomnia (ih) at beyond sleepy 2023

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) — Zevra Th...

June 3, 2023, 11:30 am

Igm biosciences announces update on igm-8444 phase 1 trial and future clinical development

– Additional data from phase 1 combination with FOLFIRI continues to show encouraging activity in med...

June 2, 2023, 9:30 pm

Tg therapeutics announces presentation of data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis at the 2023 consortium of multiple sclerosis centers annual

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II <...

June 2, 2023, 1:15 pm

Autolus therapeutics presents positive results from pivotal phase 2 felix study in adult r/r b-all at asco

76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated i...

June 2, 2023, 11:00 am

Gbp/usd consolidates its recent gains to nearly three-week peak, us nfp report awaited

The GBP/USD pair enters a bullish consolidation phase near a two-and-half-week high touched on Friday a...

June 2, 2023, 10:29 am

General motors ($gm) boosts north american ev battery production with new cam processing complex

General Motors (NYSE: GM), a leading electric vehicle producer, and POSCO Future M have announced the second p...

June 2, 2023, 10:15 am

Gm deal strengthens its ev supply chain. the stock is rising.

General Motors and POSCO announce the next phase of their joint venture to supply EV battery materials ...

June 2, 2023, 9:45 am

First mover asia: bitcoin has reached ‘a general accumulation phase’: analyst

ALSO: BTC-20 tokens are pushing toward a $500 million market cap, and data from Glassnode shows that they have been a boon for miners. Read Full Story...

June 2, 2023, 2:29 am

Bluejay therapeutics advances in hepatitis b and d trials: successfully completes bjt-778 phase 1a study and begins phase 1b trial enrollment

SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and live...

June 1, 2023, 10:14 pm

Decibel therapeutics to present db-020 phase 1b clinical trial data at the american society of clinical oncology (asco) 2023 annual meeting

Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemo...

June 1, 2023, 8:30 pm

Why shares of genelux corporation jumped this week

Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 tri...

June 1, 2023, 5:19 pm

Why shares of disc medicine opco climbed this week

Disc Medicine is a clinical-stage biopharmaceutical company specializing in treating blood disorders. The company's lead therapy, bitopertin, is in ...

June 1, 2023, 3:10 pm

Clearside biomedical opens enrollment in odyssey phase 2b clinical trial of cls-ax (axitinib injectable suspension) in wet amd

– U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD – – ODYSSEY Topline Results Expected in Q3 2024 – ALPHARETTA, ...

June 1, 2023, 11:05 am

Usd/krw analysis as south korean trade slumps again

The USD/KRW exchange rate remained in a consolidation phase as more data revealed the dire situation of...

June 1, 2023, 10:29 am


Search within

Pages Search Results: